Traders should monitor the March 31 earnings call for financial clarity and any updates on cash runway, R&D spend, or clinical trial progress. The C-Further/Southampton collaboration adds strategic value but does not materially alter near-term financials.
Price Chart
Executive Summary
MiNK Therapeutics announced it will report Q4 and full-year 2025 financial results on March 31, 2026, alongside a corporate update on clinical progress and its iNKT cell therapy platform. The press release highlights a new collaboration with C-Further and the University of Southampton to develop a PRAME-targeted iNKT therapy for pediatric cancers, bringing non-dilutive funding and strategic validation. However, no actual financial data was disclosed in this announcement.
Key Facts
- MiNK Therapeutics will report Q4 and full-year 2025 financial results on March 31, 2026, before market open.
- Company to host a conference call at 8:30 a.m. ET to discuss results and provide a corporate update.
- New collaboration with C-Further and University of Southampton on a PRAME-targeted, TCR-engineered iNKT cell therapy for pediatric cancers.
- Collaboration includes non-dilutive funding and potential downstream commercial revenue.
- No financial results (revenue, EPS, cash position) were released in this announcement.
Financial Impact
No financial data disclosed — impact deferred to earnings release
Risk Factors
- No financial metrics provided — actual results could miss expectations.
- High cash burn typical for clinical-stage biotechs; funding needs could emerge if partnerships don't scale.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257040 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 13, 2026 7w ago | 8-K | $11.00 $12.00 | ▲ +9.09% | ▲ +10.84% | $12.44 (+13.09%) |
Aug 13, 2026 7w ago | Press Release | $11.00 $12.00 | ▲ +9.09% | ▲ +10.84% | $12.44 (+13.09%) |
Aug 6, 2026 8w ago | Press Release | $11.00 $11.23 | ▲ +2.09% | ▲ +1.49% | $12.44 (+13.09%) |
May 28, 2026 18w ago | Press Release | $12.20 $11.64 | ▼ −4.59% | ▼ −1.45% | $12.44 (+1.97%) |
May 20, 2026 19w ago | Press Release | $10.72 $12.14 | ▲ +13.25% | ▲ +12.51% | $12.44 (+16.04%) |
May 15, 2026 20w ago | 8-K | $10.72 $12.54 | ▲ +16.93% | ▲ +14.81% | $12.44 (+16.04%) |
May 15, 2026 20w ago | Press Release | $10.72 $12.54 | ▲ +16.93% | ▲ +14.81% | $12.44 (+16.04%) |
May 14, 2026 20w ago | Press Release | $10.51 $12.02 | ▲ +14.37% | ▲ +15.23% | $12.44 (+18.36%) |
May 12, 2026 20w ago | Press Release | $11.41 $12.19 | ▲ +6.84% | ▲ +8.56% | $12.44 (+9.03%) |
May 8, 2026 20w ago | Press Release | $10.95 $11.82 | ▲ +7.95% | ▲ +8.25% | $12.44 (+13.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access